361 related articles for article (PubMed ID: 10353249)
1. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.
Ona VO; Li M; Vonsattel JP; Andrews LJ; Khan SQ; Chung WM; Frey AS; Menon AS; Li XJ; Stieg PE; Yuan J; Penney JB; Young AB; Cha JH; Friedlander RM
Nature; 1999 May; 399(6733):263-7. PubMed ID: 10353249
[TBL] [Abstract][Full Text] [Related]
2. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
4. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
5. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.
Murphy KP; Carter RJ; Lione LA; Mangiarini L; Mahal A; Bates GP; Dunnett SB; Morton AJ
J Neurosci; 2000 Jul; 20(13):5115-23. PubMed ID: 10864968
[TBL] [Abstract][Full Text] [Related]
6. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
7. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
8. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
9. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
10. Caspases in Huntington's disease.
Sanchez Mejia RO; Friedlander RM
Neuroscientist; 2001 Dec; 7(6):480-9. PubMed ID: 11765125
[TBL] [Abstract][Full Text] [Related]
11. Mouse models of Huntington's disease.
Menalled LB; Chesselet MF
Trends Pharmacol Sci; 2002 Jan; 23(1):32-9. PubMed ID: 11804649
[TBL] [Abstract][Full Text] [Related]
12. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.
Gil-Mohapel JM
CNS Neurosci Ther; 2012 Jan; 18(1):77-86. PubMed ID: 21501423
[TBL] [Abstract][Full Text] [Related]
13. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
14. Molecular aspects of Huntington's disease.
Walling HW; Baldassare JJ; Westfall TC
J Neurosci Res; 1998 Nov; 54(3):301-8. PubMed ID: 9819135
[TBL] [Abstract][Full Text] [Related]
15. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis.
Li SH; Lam S; Cheng AL; Li XJ
Hum Mol Genet; 2000 Nov; 9(19):2859-67. PubMed ID: 11092762
[TBL] [Abstract][Full Text] [Related]
16. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease.
Menalled L; Zanjani H; MacKenzie L; Koppel A; Carpenter E; Zeitlin S; Chesselet MF
Exp Neurol; 2000 Apr; 162(2):328-42. PubMed ID: 10739639
[TBL] [Abstract][Full Text] [Related]
17. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.
Nguyen T; Hamby A; Massa SM
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11840-5. PubMed ID: 16087879
[TBL] [Abstract][Full Text] [Related]
18. Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington's disease.
Paul BD; Sbodio JI; Xu R; Vandiver MS; Cha JY; Snowman AM; Snyder SH
Nature; 2014 May; 509(7498):96-100. PubMed ID: 24670645
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of G-protein coupled receptors in Huntington's disease.
Dowie MJ; Scotter EL; Molinari E; Glass M
Pharmacol Ther; 2010 Nov; 128(2):305-23. PubMed ID: 20708032
[TBL] [Abstract][Full Text] [Related]
20. Huntington's disease: from molecular pathogenesis to clinical treatment.
Ross CA; Tabrizi SJ
Lancet Neurol; 2011 Jan; 10(1):83-98. PubMed ID: 21163446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
